ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bullishRed Hawk Mining
05 Feb 2025 11:57

Red Hawk (RHK AU): Fortescue Secures 78% And Bumps to A$1.20/Share

This is done. Trading at terms. If in, tender. Or sell in the market. If not in, look elsewhere.  Unless Red Hawk dips below terms.

Logo
437 Views
Share
05 Feb 2025 10:41

Insignia Financial (IFL AU): Three's A Crowd As Brookfield Joins Bain And CC Capital

All three Offers remain non-binding. My guess is that Tanarra is supportive of a $4.60/share firm Offer. Trading a couple spreads through terms....

Logo
433 Views
Share
04 Feb 2025 13:37

Tam Jai (2217 HK) Suspended: Expect Toridoll (3397 JP) To Make An Offer

Tam Jai, an operator of Asia noodle restaurants, is suspended pursuant to the Code. Toridoll (3397 JP) controls 74.61%. Expect a Scheme. An Offer...

Logo
672 Views
Share
bullishVesync
04 Feb 2025 09:23

Vesync (2148 HK): Trading Wide Ahead Of The Scheme Vote

This is done. IF payment late-May, I'd pay up to HK$5.35/share for a gross/annualised return of 4.5%/15%. If small, illiquid arbs are your bent,...

Logo
719 Views
Share
bullishSelfWealth Ltd
03 Feb 2025 11:27

SelfWealth (SWF AU): Peter Thiel-Backed Svava Crashes Bell's Offer

We have a (more than likely) competing bidding situation. If small, illiquid arbs are your bent, look to enter around Svava's non-binding terms and...

Logo
416 Views
Share
x